Could a Once-a-Day inhaler replace frequent treatments for COPD emergencies?

NCT ID NCT04655170

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial is testing whether giving long-acting bronchodilators (formoterol and revefenacin) to patients hospitalized with a COPD flare-up can improve breathing as well as or better than the standard short-acting medications (albuterol and ipratropium). The study will compare the two approaches in about 60 adults aged 40 and older who are admitted with a COPD exacerbation. The goal is to see if the long-acting option is feasible, safe, and effective in this setting, potentially simplifying treatment and improving symptom control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Long-acting bronchodilators (formoterol and revefenacin) compared with short-acting bronchodilators (albuterol and ipratropium)
What this could lead to
If effective, this could lead to a more convenient and effective treatment for COPD flare-ups in the hospital, potentially reducing the number of doses needed and improving patient comfort.
What could go wrong
This is a small, early-stage trial (60 patients) that may not show a clear benefit. Long-acting bronchodilators may not be as effective or safe as the standard short-acting drugs in acute hospital settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD EXACERBATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Tennessee Medical Center

    Knoxville, Tennessee, 37920-6999, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.